Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics

Journal of Addictive Diseases

Volumn 28, Issue 1, 2009, Pages 57-63

  Winstock, Adam R ^a,b,c   Lea, Toby ^a   Jackson, Anthony P ^a  

^a Drug Health Services   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Buprenorphine; Diversion; Misuse; Motives; Supervision

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MISUSE; DRUG USE; FEMALE; HEALTH CENTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTIVATION; OPIATE ADDICTION; PATIENT COMPLIANCE; PATIENT MONITORING; QUALITY CONTROL; STRUCTURED INTERVIEW; SUBSTITUTION THERAPY; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADULT; BUPRENORPHINE; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; MOTIVATION; NARCOTICS; NEW SOUTH WALES; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; SUBSTANCE ABUSE TREATMENT CENTERS; YOUNG ADULT;

EID: 60749092493     PISSN: 10550887     EISSN: 15450848     Source Type: Journal    
DOI: 10.1080/10550880802545036     Document Type: Article

References (22)

1. Department of Health. Drug misuse and dependence: guidelines on clinical management. London: The Stationery Office; 1999.
2. NSW Department of Health. New South Wales Opioid Treatment Program clinical guidelines for methadone and buprenorphine treatment of opioid dependence. Sydney: NSW Department of Health; 2006.
3. National Drug Strategy. National policy on methadone treatment. Canberra: Commonwealth Department of Health and Family Services; 1998.
4. Lintzeris N, Lenne M, Ritter A. Methadone injecting in Australia: a tale of two cities. Addiction. 1999;94:1175-78.
5. Ritter A, Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev. 2005;24:347-52.
6. O'Brien S, Black E, Degenhardt L, Roxburgh A, Campbell G, de Graaff B, et al. Australian Drug Trends 2006: Findings from the Illicit Drug Reporting System (IDRS). NDARC Monograph No. 60. Sydney: National Drug and Alcohol Research Centre; 2007.
7. Caplehorn JRM, Drummer OH. Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines. Aust N Z J Public Health. 2002;26:358-63.
8. Darke S, Ross J, Hall W. Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. Drug Alcohol Depend. 1996;43:191-8.
9. NSW Health Department. NSW Policy for the Use of Buprenorphine in the Treatment of Opioid Dependence: Sydney: NSW Health Department; 2001.
10. Victorian Department of Human Services. Policy for maintenance pharmacotherapy for opioid dependence. Melbourne: Victorian Department of Human Services; 2006.
11. Nielsen S, Dietze P, Dunlop A, Muhleisen P, Lee N, Taylor D. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. Drug Alcohol Rev. 2007;26:143-51.
12. Winstock AR, Lea T. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Subst Use Misuse. 2008, in press.
13. Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction. 2005;100:197-205.
14. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci Int. 2001;121:65-9.
15. Kintz P. A new series of 13 buprenorphine-related deaths. Clin Biochem. 2002;35:513-6.
16. Winstock AR, Lea T, Madden A, Bath N. Knowledge about buprenorphine andmethadone among those receiving treatment for opioid dependence. Drug-Educ Prev Polic. 2008;15:395-409.
17. Fountain J, Strang J, Gossop M, Farrel M, Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction. 2000;95:393-406.
18. Fraser S. Diversion and injection of opioid pharmacotherapies in Australia: how and why and what role for policy? In: APSAD Conference 2006; Cairns, Australia; 2006.
19. Horyniak D, Armstrong S, Higgs P, Wain D, Aitken C. Buprenorphine injection in Melbourne: views from current injectors. In: APSAD Conference 2006; Cairns, Australia; 2006.
20. Fraser S, valentine k, Treloar C, Macmillan K. Methadone maintenance treatment in New South Wales and Victoria: Takeaways, diversion and other key issues. Sydney: National Centre in HIV Social Research, The University of New South Wales; 2007.
21. Wolff K, Rostami-Hodjegan A, Hay AW, Raistrick D, Tucker G. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction. 2000;95:1771-83.
22. Winstock AR, Lea T, Sheridan J. What is diversion of supervised buprenorphine and how common is it? J Addict Dis. 2007; in press.